Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
21.57
+0.04 (0.19%)
Dec 20, 2024, 4:00 PM EST - Market closed
Jasper Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Cash & Equivalents | 92.5 | 86.89 | 38.25 | 84.7 | 19.84 | 27.16 |
Cash & Short-Term Investments | 92.5 | 86.89 | 38.25 | 84.7 | 19.84 | 27.16 |
Cash Growth | -10.94% | 127.16% | -54.84% | 326.96% | -26.97% | - |
Other Receivables | 0.25 | 0.25 | 0.91 | 0.55 | 0.6 | - |
Receivables | 0.25 | 0.25 | 0.91 | 0.55 | 0.6 | - |
Prepaid Expenses | 1.09 | 1.12 | 1.61 | 2.29 | 0.04 | - |
Other Current Assets | 0.97 | 0.68 | 0.96 | 0.29 | 0.2 | - |
Total Current Assets | 94.81 | 88.94 | 41.73 | 87.83 | 20.69 | 27.16 |
Property, Plant & Equipment | 3.18 | 4.19 | 5.45 | 4.83 | 2.03 | - |
Other Long-Term Assets | 1.43 | 1.76 | 1.18 | 0.99 | 0.64 | 0.05 |
Total Assets | 99.41 | 94.89 | 48.36 | 93.65 | 23.36 | 27.21 |
Accounts Payable | 3.09 | 4.15 | 1.77 | 3.92 | 1.42 | 0.62 |
Accrued Expenses | 7.47 | 6.94 | 4.24 | 2.81 | 2.05 | 1.37 |
Current Portion of Leases | 1.06 | 0.97 | 0.87 | 0.51 | - | - |
Other Current Liabilities | 0.85 | 0.32 | 0.19 | 0.79 | 0.55 | - |
Total Current Liabilities | 12.46 | 12.37 | 7.07 | 8.02 | 4.01 | 1.99 |
Long-Term Leases | 1.01 | 1.81 | 2.79 | 2.38 | 1.62 | - |
Long-Term Unearned Revenue | 2.26 | 2.26 | 2.26 | 0.6 | 0.6 | - |
Other Long-Term Liabilities | - | - | 0.26 | 13.14 | 8.41 | 4.12 |
Total Liabilities | 15.73 | 16.45 | 12.37 | 24.14 | 14.65 | 6.11 |
Common Stock | 0 | 0 | - | 0 | 0 | 0.01 |
Additional Paid-In Capital | 300.23 | 248.04 | 141.12 | 136.96 | 1.68 | 0.4 |
Retained Earnings | -216.55 | -169.6 | -105.14 | -67.45 | -36.81 | -5.14 |
Total Common Equity | 83.68 | 78.44 | 35.99 | 69.52 | -35.13 | -4.73 |
Shareholders' Equity | 83.68 | 78.44 | 35.99 | 69.52 | 8.71 | 21.1 |
Total Liabilities & Equity | 99.41 | 94.89 | 48.36 | 93.65 | 23.36 | 27.21 |
Total Debt | 2.07 | 2.79 | 3.65 | 2.89 | 1.62 | - |
Net Cash (Debt) | 90.43 | 84.1 | 34.6 | 81.82 | 18.21 | 27.16 |
Net Cash Growth | -10.33% | 143.07% | -57.71% | 349.19% | -32.95% | - |
Net Cash Per Share | 6.65 | 8.06 | 9.48 | 71.81 | 105.29 | - |
Filing Date Shares Outstanding | 15 | 15.06 | 10.94 | 4.95 | 10.16 | - |
Total Common Shares Outstanding | 15 | 11.16 | 4.62 | 4.95 | 9.81 | - |
Working Capital | 82.35 | 76.56 | 34.67 | 79.81 | 16.67 | 25.17 |
Book Value Per Share | 5.58 | 7.03 | 7.78 | 14.04 | -3.58 | - |
Tangible Book Value | 83.68 | 78.44 | 35.99 | 69.52 | -35.13 | -4.73 |
Tangible Book Value Per Share | 5.58 | 7.03 | 7.78 | 14.04 | -3.58 | - |
Machinery | 2.86 | 2.62 | 2.35 | 1.92 | 0.44 | - |
Leasehold Improvements | 2.71 | 2.48 | 2.48 | 2.06 | 0.26 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.